Unlike conventional thermogenic agents, CL19183 appears to modulate multiple metabolic pathways, including AMPK activation, β3-AR stimulation, and GLP-1 upregulation, supporting its efficacy in reducing adiposity and improving lipid profiles and insulin sensitivity and suggesting potential benefits for obesity-related conditions such as type 2 diabetes and cardiovascular disease. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.